

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

**INSIDE INFORMATION ANNOUNCEMENT
THE H SHARE FULL CIRCULATION
LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE**

INTRODUCTION

Reference is made to the announcement (the “**Announcement**”) of Suzhou Basecare Medical Corporation Limited (the “**Company**”) dated February 24, 2022 in relation to the Company receiving the official approval from the China Securities Regulatory Commission regarding the implementation of the full circulation of H shares of the Company (the “**H Shares**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

LISTING APPROVAL

The Company is pleased to announce that the approval for the listing (the “**Listing Approval**”) of and permission to deal in 192,592,582 H Shares (the “**Converted H Shares**”), representing the maximum total number of domestic shares and unlisted foreign shares of the Company (the “**Unlisted Shares**”) to be converted under the Conversion and Listing, was granted by the Stock Exchange on March 3, 2022.

SHAREHOLDING STRUCTURE

The Conversion and Listing will involve a total of 16 participating holders (the “**Participating Shareholders**”) of the 192,592,582 Unlisted Shares. Set out below is the percentage holding in the Company in relation to the Participating Shareholders upon completion of the Conversion and Listing:

Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued H Shares upon completion of the Conversion and Listing
Dr. LIANG BO (梁波)	55,231,640	20.19%
Guangzhou DaAn Gene Technology Co., Ltd (廣州市達安基因科技有限公司)	8,133,798	2.97%
Guangzhou Darui Biotechnology Co., Ltd. (廣州市達瑞生物技術股份有限公司)	4,748,225	1.74%
Suzhou Basecare Investment Management Enterprise (Limited Partnership) (蘇州貝康投資管理企業 (有限合夥))	36,090,379	13.19%
Suzhou Industrial Park Seed Zhengze Yihao Venture Capital Enterprise (Limited Partnership) (蘇州工業園區原點正則壹號創 業投資企業 (有限合夥))	12,299,422	4.50%
Zhejiang Shuangjing Investment Co., Ltd (浙江雙井投資有限公司)	3,355,185	1.23%
Ms. JI Dongmei (吉冬梅)	5,591,993	2.04%
Suzhou Industrial Park Sungent Bio-Venture Capital Investment Enterprise (Limited Partnership) (蘇州工業園區新建元生物創業 投資企業 (有限合夥))	11,418,525	4.17%

Name of the Participating Shareholders	Number of Converted H Shares	Approximate percentage of total issued H Shares upon completion of the Conversion and Listing
Beijing Zhongcheng Fangyuan Phase II Investment Center (Limited Partnership) (北京中誠方圓二期投資中心 (有限合夥))	15,189,172	5.55%
Guangzhou DaAn Jinghan Medical Health Industry Investment Enterprise (Limited Partnership) (廣州達安京漢醫療健康產業投 資企業 (有限合夥))	3,797,286	1.39%
Zhangjiagang Broad Vision Investment Fund (Limited Partnership) (張家港博華創業投資 合夥企業 (有限合夥))	11,969,242	4.38%
Suzhou MING Bioventures Fund I Venture Capital, L.P. (蘇州聚明中泓方仁創業投資合 夥企業 (有限合夥))	3,419,787	1.25%
Yingtian Jinhu Jiayi Hongsheng Investment Management Limited Partnership Corporation (鷹潭金虎嘉怡弘晟投資管理有限合夥企業)	1,709,894	0.63%
HH SPR-XIV HK Holdings Limited	7,630,348	2.79%
Zhangjiagang Broad Vision Harmony Shareholding Investment Fund (Limited Partnership) (張家港博華和瑞股權投資合夥 企業 (有限合夥))	10,227,269	3.74%
Orbimed Partners Master Fund Limited	1,780,417	0.65%
Total	<u>192,592,582</u>	<u>70.41%</u>

CONVERSION AND TRADING PROCEDURES

With the authorization of the Participating Shareholders and on their behalf, the Company will complete the cancellation registration procedure for the Unlisted Shares held by the Participating Shareholders in China Securities Depository and Clearing Corporation Limited (“**China Clearing**”) Shenzhen Branch.

The Company will complete the following procedures in connection with the Conversion and Listing:

- (a) For holders of the Unlisted Shares who are nationals of the PRC and are Participating Shareholders, with their authorization and on their behalf, the Company will appoint China Clearing as the nominee to deposit their relevant securities (the “**Relevant Securities**”) at China Securities Depository and Clearing (Hong Kong) Company Limited (“**China Clearing HK**”). China Clearing HK in its own name will deposit the Relevant Securities at Hong Kong Securities Clearing Company Limited (“**HKSCC**”). China Clearing as the nominee of such Participating Shareholders, who are PRC nationals, will handle all custody, maintenance of detailed records, cross-border settlement and corporate actions etc. relating to the Converted H Shares for the Participating Shareholders who are PRC nationals;
- (b) The Company will instruct the H share registrar of the Company, Computershare Hong Kong Investor Services Limited, in relation to the issue of the relevant share certificates of the Converted H Shares; and
- (c) The Company will make arrangements to enable the Converted H Shares be accepted as eligible securities by HKSCC for deposit, clearance and settlement in the Central Clearing and Settlement System (“**CCASS**”).

The holders of the Converted H Shares who are PRC nationals can only conduct share trading after the below arrangement procedures relating to the registration, depository and transaction settlement of the Conversion and Listing are completed:

- (a) The Company will apply to China Clearing, Shenzhen Branch for the maintenance of the detailed records of the initial holding of the Converted H Shares held by the relevant holders. Meanwhile, the Company will submit applications for a domestic transaction commission code and abbreviation, which will be confirmed by China Clearing, Shenzhen Branch pursuant to the authorization of the Shenzhen Stock Exchange (the “**Shenzhen Stock Exchange**”).

- (b) The Shenzhen Stock Exchange authorizes Shenzhen Securities Communication Co., Ltd. to provide services relating to trading entrustment orders and transmission of trading messages between a domestic securities company, China CICC Fortune Securities Co., Ltd. (中國中金財富證券有限公司), (the “**Domestic Securities Company**”) and a Hong Kong securities company, China International Capital Corporation Hong Kong Securities Limited (中國國際金融(香港)有限公司), (the “**Hong Kong Securities Company**”) for the Converted H Shares, and the real-time market forwarding services of the relevant H Shares;
- (c) According to the “Circular of the State Administration of Foreign Exchange on Issues concerning the Administration of Foreign Exchange Involved in Overseas Listing” (《國家外匯管理局關於境外上市外匯管理有關問題的通知》), the holders of the Converted H Shares who are PRC nationals should complete the overseas shareholding registration with the local foreign exchange administration bureau before the shares are sold, and after the overseas shareholding registration, open a specified bank account for the purpose of holding of shares overseas by onshore investors at a designated onshore bank with relevant qualifications, and open a specified fund account for the purpose of H share “full circulation” at the Domestic Securities Company. The Domestic Securities Company shall open a securities trading account for H share “full circulation” at the Hong Kong Securities Company; and
- (d) The holders of the Converted H Shares who are PRC nationals should, through the specified account, submit entrusted trading order of the Converted H Shares through the Domestic Securities Company. The relevant orders of the holders of the Converted H Shares will be submitted to the Stock Exchange for trading through the securities trading account opened by the Domestic Securities Company at the the Hong Kong Securities Company. After completion of the transaction, the Hong Kong Securities Company and China Clearing HK, China Clearing HK and China Clearing, China Clearing and the Domestic Securities Company, the Domestic Securities Company and the holders of the Converted H Shares will conduct settlement respectively.

Further announcement(s) will be made by the Company when and where appropriate.

SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, March 6, 2022

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. CHAU Kwok Keung as independent non-executive Directors.